Reports
Sale
Global Monoclonal Antibodies Market Size, Growth, Trends: By Production Type: In Vitro, In Vivo; By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Other; By End User: Hospitals, Specialty Clinics, Others; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Global Monoclonal Antibodies Market Outlook
The global monoclonal antibodies market size was valued at USD 210.6 billion in 2023, driven by the rising prevalence of chronic and infectious diseases across the globe. The market is expected to grow at a CAGR of 11.5% during the forecast period of 2024-2032, with the values likely to rise from USD 234.9 billion in 2024 to USD 562.8 billion by 2032.
Global Monoclonal Antibodies Market Overview
Monoclonal antibodies have therapeutic potential as they carry the ability to enhance, restore, modify, or mimic the immune system’s attack on certain unwanted cells, like cancer cells. They are a form of targeted drug therapy that is administrated intravenously. The rising prevalence of chronic diseases and infectious diseases drives the need for effective monoclonal antibody therapies to treat various medical conditions.
The global burden of chronic diseases is rapidly increasing which is expected to bolster the monoclonal antibodies market growth in coming years. According to the World Health Organisation (WHO), chronic diseases account for 41 million deaths annually. It is further estimated that cancer and diabetes cause 9.3 million and 2 million deaths per year, respectively. Monoclonal antibodies, with their ability to target disease mechanisms, can offer a promising treatment solution to combat these rising cases of global mortality due to chronic disease.
The market is witnessing increased strategic partnerships, collaborations, and research and development (R&D) investments from various public and private organizations. In September 2023, the United States Department of Health and Human Services (HHS) announced an extension of its partnership with Regeneron Pharmaceuticals. The agreement, valued at USD 326 million, is expected to support the development of a next-generation monoclonal antibody for COVID-19 prevention and is a part of HHS’s Project NextGen. The contract states that the list price of the new product if commercialized, should either be equivalent to or lesser than its approved price in comparable markets globally. Such public-private partnerships are anticipated to greatly impact the monoclonal antibodies market size in the forecast period.
Other factors that influence the market dynamics include the growing adoption of monoclonal antibody therapies in the healthcare sector, heightened patient awareness, and improvements in the regulatory landscape which enables the availability of new therapeutic options in the markets. Moreover, the rise in research initiatives aimed at developing innovative monoclonal antibody therapies is likely to augment the market size.
Global Monoclonal Antibodies Market Trends
| Key Trend | Impact |
| Rapid Technological Advancements | Technological advancements in biotechnology and genetic engineering have fuelled the development as well as the production of monoclonal antibodies (mAbs). Innovations like recombinant DNA technology, hybridoma technology, and phage display have improved the specificity and efficacy of monoclonal antibodies against their targets. This trend expands monoclonal antibody applications across a wide range of diseases, including cancer, autoimmune diseases, and infectious diseases, and helps in attracting significant research and development investment. |
| Growing Demand for Personalized Medicine | The growing demand for personalized medicine and the increasing emphasis on understanding the genetic basis of diseases have made a significant impact on the market. Monoclonal antibody therapies can be tailored to individual patient profiles, based on genetic markers and disease characteristics. Such customization opportunities can improve treatment outcomes and reduce side effects, driving the monoclonal antibodies market demand to facilitate a targeted approach in therapy development. |
| Improvements in Regulatory Framework | Supportive regulatory environments such as fast-track designations, orphan drug status, and breakthrough therapy designations, have greatly impacted the market. Such regulatory reforms accelerate the approval process for promising monoclonal antibody therapies. This also encourages pharmaceutical companies to invest in the development of monoclonal antibodies for unmet medical needs of patients across the world. Moreover, the evolving regulatory framework speeds up the availability of innovative treatments to patients. |
| Expansion into Emerging Markets | The rising healthcare expenditures, improving healthcare infrastructure, and growing public awareness of advanced therapies have accelerated the expansion of the monoclonal antibodies market share into emerging economies. These emerging markets offer potential for monoclonal antibodies due to their large patient populations and increasing incidence of diseases treatable by the therapeutic. Further, key market players are strategically entering these markets, thus driving market growth and accessibility to monoclonal antibodies therapies. |
Global Monoclonal Antibodies Market Segmentation
Market Breakup by Production Type
- In Vitro
- In Vivo
The market segmentation by production includes in vitro and in vivo production methods. This market segment illustrates the different approaches utilized to produce monoclonal antibodies.
Market Breakup by Application
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Other
Monoclonal antibodies are utilized in various therapeutic areas including oncology, autoimmune diseases, infectious diseases, neurological diseases, and others, addressing a wide range of medical conditions. The applications of monoclonal antibodies are rapidly expanding to treat a range of chronic and infectious diseases. This increased use is expected to augment the market scope and elevate monoclonal antibodies market value.
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
End-users of monoclonal antibodies include hospitals, and specialty clinics, among others. These healthcare facilities provide access to these biologic agents for diverse patient populations and clinical needs.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The monoclonal antibodies market analysis offers insights into major regional markets such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market segment which can be attributed to the presence of an advanced healthcare infrastructure along with heightened patient awareness which enables more people to seek monoclonal antibody treatment options. Further, the rise in the prevalence of chronic diseases, with recent data suggesting that 6 in 10 Americans are affected by at least 1 chronic disease , directly impacts the market demand in the region.
Global Monoclonal Antibodies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline PLC
- Merck & Co. Inc
- Daiichi Sankyo Company, Limited
- Abbott Laboratories
- AstraZeneca PLC
- Eli Lilly and Company
- Johnson & Johnson
- Bristol Myers Squibb
- F. Hoffmann La Roche Ltd.
- Biogen Inc.
- Sanofi
- Novo Nordisk A/S
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Production Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Global Monoclonal Antibodies Market Report
- How will the market landscape evolve in the forecast period?
- What future trends can be anticipated in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to experience expedited growth during the forecast period?
- Which production type will lead the market growth?
- Which end user is expected to dominate the respective market segment?
- What are the key research initiatives expected to boost the market value during the forecast period?
- Which application is poised to make the highest impact on the monoclonal antibodies market growth?
- What are the market shares, strategies, and product portfolios of the leading players in the market?
- How is the regulatory landscape shaping the market?
- What are the market dynamics, trends, and growth prospects in the key regional markets?
- How is technology innovation impacting the development of monoclonal antibodies?
- What are the investment opportunities and potential risks associated with the market?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Monoclonal Antibodies Market Overview
3.1 Global Monoclonal Antibodies Market Historical Value (2017-2023)
3.2 Global Monoclonal Antibodies Market Forecast Value (2024-2032)
4 Global Monoclonal Antibodies Market Landscape*
4.1 Global Monoclonal Antibodies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Monoclonal Antibodies: Product Landscape
4.2.1 Analysis by Production Type
4.2.2 Analysis by Application
5 Global Monoclonal Antibodies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Monoclonal Antibodies Market Segmentation (2017-2032)
6.1 Global Monoclonal Antibodies Market (2017-2032) by Production Type
6.1.1 Market Overview
6.1.2 In Vitro
6.1.3 In Vivo
6.2 Global Monoclonal Antibodies Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Autoimmune Diseases
6.2.4 Infectious Diseases
6.2.5 Neurological Diseases
6.2.6 Other
6.3 Global Monoclonal Antibodies Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Specialty Clinics
6.3.4 Others
6.4 Global Monoclonal Antibodies Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Monoclonal Antibodies Market (2017-2032)
7.1 North America Monoclonal Antibodies Market (2017-2032) by Production Type
7.1.1 Market Overview
7.1.2 In Vitro
7.1.3 In Vivo
7.2 North America Monoclonal Antibodies Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Oncology
7.2.3 Autoimmune Diseases
7.2.4 Infectious Diseases
7.2.5 Neurological Diseases
7.2.6 Other
7.3 North America Monoclonal Antibodies Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Monoclonal Antibodies Market (2017-2032)
8.1 Europe Monoclonal Antibodies Market (2017-2032) by Production Type
8.1.1 Market Overview
8.1.2 In Vitro
8.1.3 In Vivo
8.2 Europe Monoclonal Antibodies Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Oncology
8.2.3 Autoimmune Diseases
8.2.4 Infectious Diseases
8.2.5 Neurological Diseases
8.2.6 Other
8.3 Europe Monoclonal Antibodies Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Monoclonal Antibodies Market (2017-2032)
9.1 Asia Pacific Monoclonal Antibodies Market (2017-2032) by Production Type
9.1.1 Market Overview
9.1.2 In Vitro
9.1.3 In Vivo
9.2 Asia Pacific Monoclonal Antibodies Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Oncology
9.2.3 Autoimmune Diseases
9.2.4 Infectious Diseases
9.2.5 Neurological Diseases
9.2.6 Other
9.3 Asia Pacific Monoclonal Antibodies Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Monoclonal Antibodies Market (2017-2032)
10.1 Latin America Monoclonal Antibodies Market (2017-2032) by Production Type
10.1.1 Market Overview
10.1.2 In Vitro
10.1.3 In Vivo
10.2 Latin America Monoclonal Antibodies Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Oncology
10.2.3 Autoimmune Diseases
10.2.4 Infectious Diseases
10.2.5 Neurological Diseases
10.2.6 Other
10.3 Latin America Monoclonal Antibodies Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Monoclonal Antibodies Market (2017-2032)
11.1 Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Production Type
11.1.1 Market Overview
11.1.2 In Vitro
11.1.3 In Vivo
11.2 Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Oncology
11.2.3 Autoimmune Diseases
11.2.4 Infectious Diseases
11.2.5 Neurological Diseases
11.2.6 Other
11.3 Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 JAPAN PMDA
12.1.4 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Novartis AG
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Pfizer Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 GlaxoSmithKline PLC
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Merck & Co. Inc
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Daiichi Sankyo Company, Limited
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Abbott Laboratories
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 AstraZeneca PLC
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Eli Lilly and Company
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Johnson & Johnson
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Bristol Myers Squibb
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 F. Hoffmann La Roche Ltd.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Biogen Inc.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Sanofi
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Novo Nordisk A/S
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Monoclonal Antibodies Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 210.6 billion in 2023 driven by the rising prevalence of chronic and infectious diseases.
The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2024-2032, likely to reach a market value of USD 562.8 billion by 2032.
Heightened patient awareness and increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is increased strategic partnerships, collaborations, and research and development investments from various public and private organizations. In September 2023, the United States Department of Health, and Human Services (HHS) announced its partnership extension with Regeneron Pharmaceuticals. Valued at USD 326 million, the agreement is anticipated to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
Based on the production type, the market is segmented into in vitro and in vivo production methods.
End-users of monoclonal antibodies include hospitals, and specialty clinics, among others.
Applications of monoclonal antibodies include oncology, autoimmune diseases, infectious diseases, neurological diseases, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc, Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Johnson & Johnson, Bristol Myers Squibb, F. Hoffmann La Roche Ltd., Biogen Inc., Sanofi, and Novo Nordisk A/S.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER